Founders Capital Management LLC held its position in Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,580 shares of the medical research company’s stock at the end of the third quarter. Amgen accounts for 1.0% of Founders Capital Management LLC’s holdings, making the stock its 27th largest position. Founders Capital Management LLC’s holdings in Amgen were worth $1,765,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of AMGN. Advisory Services Network LLC increased its position in Amgen by 11.2% in the third quarter. Advisory Services Network LLC now owns 10,793 shares of the medical research company’s stock worth $1,800,000 after buying an additional 1,085 shares during the period. Sadoff Investment Management LLC acquired a new position in Amgen during the third quarter valued at approximately $220,000. Catawba Capital Management VA increased its position in Amgen by 31.8% in the third quarter. Catawba Capital Management VA now owns 5,320 shares of the medical research company’s stock valued at $887,000 after buying an additional 1,285 shares during the last quarter. Oliver Luxxe Assets LLC increased its position in Amgen by 13.8% in the third quarter. Oliver Luxxe Assets LLC now owns 3,849 shares of the medical research company’s stock valued at $642,000 after buying an additional 467 shares during the last quarter. Finally, R.H. Dinel Investment Counsel Inc. increased its position in Amgen by 1.7% in the third quarter. R.H. Dinel Investment Counsel Inc. now owns 22,400 shares of the medical research company’s stock valued at $3,737,000 after buying an additional 375 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) traded down 0.25% during mid-day trading on Monday, reaching $145.07. 2,411,697 shares of the company’s stock were exchanged. The firm has a market cap of $107.92 billion, a price-to-earnings ratio of 14.52 and a beta of 1.15. The stock has a 50-day moving average of $151.01 and a 200-day moving average of $160.49. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $176.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, October 27th. The medical research company reported $3.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.79 by $0.23. The business earned $5.81 billion during the quarter, compared to the consensus estimate of $5.73 billion. Amgen had a net margin of 33.63% and a return on equity of 29.27%. The firm’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.72 EPS. Analysts anticipate that Amgen Inc. will post $11.56 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 8th. Investors of record on Wednesday, November 16th will be paid a $1.00 dividend. This represents a $4.00 annualized dividend and a yield of 2.75%. The ex-dividend date of this dividend is Monday, November 14th. Amgen’s payout ratio is 39.92%.

COPYRIGHT VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/28/founders-capital-management-llc-has-1765000-stake-in-amgen-inc-amgn.html.

Several equities analysts have commented on AMGN shares. Vetr downgraded shares of Amgen from a “hold” rating to a “sell” rating and set a $166.35 target price on the stock. in a research report on Monday, August 1st. Goldman Sachs Group Inc. reissued a “buy” rating and set a $204.00 target price on shares of Amgen in a research report on Thursday, September 8th. Cowen and Company reissued a “buy” rating on shares of Amgen in a research report on Monday, September 19th. Leerink Swann reissued a “market perform” rating and set a $163.00 target price (down from $193.00) on shares of Amgen in a research report on Friday, October 28th. Finally, Piper Jaffray Cos. set a $193.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Thursday, September 15th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $182.04.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.